피임 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문별 예측(2024-2030년)

Contraceptive Market Growth & Trends:

The global contraceptive market size is anticipated to reach USD 44.04 billion by 2030 and is anticipated to grow at a CAGR of 5.92% during the forecast period, according to a new report by Grand View Research, Inc. The growing prevalence of Sexually Transmitted Infections (STIs), especially HIV, and the growing awareness of contraception in developing countries is expected to drive the industry growth during the forecast period. The presence of high unmet contraceptive needs coupled with the implementation of favorable government policies is expected to significantly contribute to market growth.

The government spending on contraceptives is growing rapidly. This is expected to drive the growth of the market over the forecast period. This investment typically supports initiatives such as subsidized or free contraceptive services, educational campaigns, and distribution programs. Such efforts increase accessibility to contraceptives and raise awareness about family planning and reproductive health, boosting the growth of the market. According to the Family Planning 2030 report, the U.S. donated the largest funding for family planning in 2022, accounting for around USD 582.9 million (43%), followed by the Netherlands (USD 217.4 million (16%)), UK (USD 174.7 million (13%)), Sweden (USD 121.3 million (9%)) and Canada (USD 88.3 million (7%)).

Due to the highly competitive nature of the market, major companies are focusing on significant investments in Research and Development (R&D) and adopting various strategies such as mergers and acquisitions and expanding their product pipelines. For instance, in December 2023, Quotient Sciences, a drug development company based in Nottingham, announced the initiation of the first trial for a hormone-free male birth control pill called YCT-529.

Contraceptive Market Report Highlights:

• Based on product, the contraceptive device segment dominated the market with the largest revenue share in 2023. This is attributed to the higher success rates and the single-use nature of the devices.
• Moreover, the contraceptive drugs segment is expected to witness the fastest CAGR during the forecast period owing to the easy accessibility, affordability, and significant success rates pertaining to these medications.
• The North America region held the largest market share in 2023. This can be attributed to the high user awareness levels and easy product availability
• In June 2023, DKT Healthcare Uganda launched a new condom variant called Kiss Extra Time designed to prolong sexual performance and enhance the intimate experience for couples. The condom is available for purchase at USD 0.16 in drug shops and pharmacies across Uganda, alongside other variants such as Kiss Passion Fruit, Kiss Strawberry, Kiss Classic, Kiss Chocolate, and Kiss Studded, all designed to cater to diverse preferences.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
  • 1.8.2. Volume Price Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Government and NGO initiatives to promote contraceptive methods
    • 3.2.1.2. Increasing prevalence of unwanted pregnancies and rising number of women with unmet contraceptive drugs and devices needs
    • 3.2.1.3. Increasing prevalence of sexually transmitted diseases (STDs)
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Rapidly aging population and rising prevalence of infertility
    • 3.2.2.2. Adverse effects associated with the use of contraceptive drugs and devices
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Product Business Analysis

• 4.1. Product Market Share, 2023 & 2030
• 4.2. Product Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Contraceptive Drugs
  • 4.4.1. Contraceptive drugs market, 2018 - 2030 (USD Million)
  • 4.4.2. Contraceptive Pills
    • 4.4.2.1. Contraceptive pills market, 2018 - 2030 (USD Million)
  • 4.4.3. Patch
    • 4.4.3.1. Patch market, 2018 - 2030 (USD Million)
  • 4.4.4. Injectables
    • 4.4.4.1. Injectables market, 2018 - 2030 (USD Million)
• 4.5. Contraceptive Devices
  • 4.5.1. Contraceptive devices market, 2018 - 2030 (USD Million)
  • 4.5.2. Condom
    • 4.5.2.1. Condom market, 2018 - 2030 (USD Million)
    • 4.5.2.2. Male Condom
    • 4.5.2.2.1.Male condom market, 2018 - 2030 (USD Million)
    • 4.5.2.3. Female Condom
    • 4.5.2.3.1.Female condom market, 2018 - 2030 (USD Million)
  • 4.5.3. Subdermal Implants
    • 4.5.3.1. Subdermal implants market, 2018 - 2030 (USD Million)
  • 4.5.4. Intra-Uterine Devices (IUDs)
    • 4.5.4.1. Intra-Uterine devices (IUDs) market, 2018 - 2030 (USD Million)
    • 4.5.4.2. Copper IUD
    • 4.5.4.2.1.Copper IUD market, 2018 - 2030 (USD Million)
    • 4.5.4.3. Hormonal IUD
    • 4.5.4.3.1.Hormonal IUD market, 2018 - 2030 (USD Million)
  • 4.5.5. Vaginal Ring
    • 4.5.5.1. Vaginal ring market, 2018 - 2030 (USD Million)
  • 4.5.6. Diaphragm
    • 4.5.6.1. Diaphragm market, 2018 - 2030 (USD Million)

Chapter 5. Regional Estimates & Trend Analysis by Application& Ownership

• 5.1. Regional Market Share Analysis, 2023 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.4. North America
  • 5.4.1. North America contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key country dynamic
    • 5.4.2.2. Regulatory framework
    • 5.4.2.3. Competitive insights
    • 5.4.2.4. U.S. contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.3. Canada
    • 5.4.3.1. Key country dynamic
    • 5.4.3.2. Regulatory framework
    • 5.4.3.3. Competitive insights
    • 5.4.3.4. Canada contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.4.4. Mexico
    • 5.4.4.1. Key country dynamic
    • 5.4.4.2. Regulatory framework
    • 5.4.4.3. Competitive insights
    • 5.4.4.4. Mexico contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.2. Germany
    • 5.5.2.1. Key country dynamic
    • 5.5.2.2. Regulatory framework
    • 5.5.2.3. Competitive insights
    • 5.5.2.4. Germany contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.3. UK
    • 5.5.3.1. Key country dynamic
    • 5.5.3.2. Regulatory framework
    • 5.5.3.3. Competitive insights
    • 5.5.3.4. UK contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key country dynamic
    • 5.5.4.2. Regulatory framework
    • 5.5.4.3. Competitive insights
    • 5.5.4.4. France contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key country dynamic
    • 5.5.5.2. Regulatory framework
    • 5.5.5.3. Competitive insights
    • 5.5.5.4. Italy contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key country dynamic
    • 5.5.6.2. Regulatory framework
    • 5.5.6.3. Competitive insights
    • 5.5.6.4. Spain contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.7. Denmark
    • 5.5.7.1. Key country dynamic
    • 5.5.7.2. Regulatory framework
    • 5.5.7.3. Competitive insights
    • 5.5.7.4. Denmark contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.8. Sweden
    • 5.5.8.1. Key country dynamic
    • 5.5.8.2. Regulatory framework
    • 5.5.8.3. Competitive insights
    • 5.5.8.4. Sweden contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5.9. Norway
    • 5.5.9.1. Key country dynamic
    • 5.5.9.2. Regulatory framework
    • 5.5.9.3. Competitive insights
    • 5.5.9.4. Norway contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key country dynamic
    • 5.6.2.2. Regulatory framework
    • 5.6.2.3. Competitive insights
    • 5.6.2.4. Japan contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key country dynamic
    • 5.6.3.2. Regulatory framework
    • 5.6.3.3. Competitive insights
    • 5.6.3.4. China contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key country dynamic
    • 5.6.4.2. Regulatory framework
    • 5.6.4.3. Competitive insights
    • 5.6.4.4. India contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.5. South Korea
    • 5.6.5.1. Key country dynamic
    • 5.6.5.2. Regulatory framework
    • 5.6.5.3. Competitive insights
    • 5.6.5.4. South Korea contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.6. Australia
    • 5.6.6.1. Key country dynamic
    • 5.6.6.2. Regulatory framework
    • 5.6.6.3. Competitive insights
    • 5.6.6.4. Australia contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6.7. Thailand
    • 5.6.7.1. Key country dynamic
    • 5.6.7.2. Regulatory framework
    • 5.6.7.3. Competitive insights
    • 5.6.7.4. Thailand contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key country dynamic
    • 5.7.2.2. Regulatory framework
    • 5.7.2.3. Competitive insights
    • 5.7.2.4. Brazil contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key country dynamic
    • 5.7.3.2. Regulatory framework
    • 5.7.3.3. Competitive insights
    • 5.7.3.4. Argentina contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
• 5.8. MEA
  • 5.8.1. MEA contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key country dynamic
    • 5.8.2.2. Regulatory framework
    • 5.8.2.3. Competitive insights
    • 5.8.2.4. South Africa contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key country dynamic
    • 5.8.3.2. Regulatory framework
    • 5.8.3.3. Competitive insights
    • 5.8.3.4. Saudi Arabia contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key country dynamic
    • 5.8.4.2. Regulatory framework
    • 5.8.4.3. Competitive insights
    • 5.8.4.4. UAE contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key country dynamic
    • 5.8.5.2. Regulatory framework
    • 5.8.5.3. Competitive insights
    • 5.8.5.4. Kuwait contraceptive market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. AbbVie Inc.
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial performance
    • 6.5.1.3. Product benchmarking
    • 6.5.1.4. Strategic initiatives
  • 6.5.2. Bayer AG
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial performance
    • 6.5.2.3. Product benchmarking
    • 6.5.2.4. Strategic initiatives
  • 6.5.3. Organon Group of Companies
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial performance
    • 6.5.3.3. Product benchmarking
    • 6.5.3.4. Strategic initiatives
  • 6.5.4. Pfizer Inc.
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial performance
    • 6.5.4.3. Product benchmarking
    • 6.5.4.4. Strategic initiatives
  • 6.5.5. Afaxys, Inc.
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial performance
    • 6.5.5.3. Product benchmarking
    • 6.5.5.4. Strategic initiatives
  • 6.5.6. Viatris Inc.
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial performance
    • 6.5.6.3. Product benchmarking
    • 6.5.6.4. Strategic initiatives
  • 6.5.7. Agile Therapeutics
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial performance
    • 6.5.7.3. Product benchmarking
    • 6.5.7.4. Strategic initiatives
  • 6.5.8. Johnson & Johnson Services, Inc.
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial performance
    • 6.5.8.3. Product benchmarking
    • 6.5.8.4. Strategic initiatives
  • 6.5.9. HELM AG
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial performance
    • 6.5.9.3. Product benchmarking
    • 6.5.9.4. Strategic initiatives
  • 6.5.10. Church & Dwight Co., Inc.
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial performance
    • 6.5.10.3. Product benchmarking
    • 6.5.10.4. Strategic initiatives
  • 6.5.11. Veru Inc.
    • 6.5.11.1. Overview
    • 6.5.11.2. Financial performance
    • 6.5.11.3. Product benchmarking
    • 6.5.11.4. Strategic initiatives
  • 6.5.12. China Resources (Group) Co., LTD.
    • 6.5.12.1. Overview
    • 6.5.12.2. Financial performance
    • 6.5.12.3. Product benchmarking
    • 6.5.12.4. Strategic initiatives